DECN Stock Overview
Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Decision Diagnostics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0002 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| DECN | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | 1.0% |
| 1Y | -99.0% | -9.6% | 21.9% |
Return vs Industry: DECN underperformed the US Healthcare Services industry which returned -8.1% over the past year.
Return vs Market: DECN underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| DECN volatility | |
|---|---|
| DECN Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DECN has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DECN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Keith Berman | www.decisiondiagnostics.co |
Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate!
Decision Diagnostics Corp. Fundamentals Summary
| DECN fundamental statistics | |
|---|---|
| Market cap | US$380.00 |
| Earnings (TTM) | -US$8.29m |
| Revenue (TTM) | US$2.13m |
0.0x
P/S Ratio0.0x
P/E RatioIs DECN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DECN income statement (TTM) | |
|---|---|
| Revenue | US$2.13m |
| Cost of Revenue | US$1.67m |
| Gross Profit | US$462.23k |
| Other Expenses | US$8.75m |
| Earnings | -US$8.29m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did DECN perform over the long term?
See historical performance and comparison